1. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–74.
2. Johnson & Johnson. Janssen marks first approval worldwide for TECVAYLI® (teclistamab) with EC authorisation of first-in-class bispecific antibody for the treatment of patients with multiple myeloma [media release]. 24 Aug 2022. https://www.jnj.com.
3. Janssen Biologics B.V. TECVAYLI: EU summary of product characteristics. 2022. https://ec.europa.eu. Accessed 29 Sep 2022.
4. U.S. Food & Drugs Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma [media release]. 26 Oct 2022. https://www.fda.gov
5. Johnson & Johnson. Pharmaceutical pipeline. 2022. https://www.investor.jnj.com. Accessed 29 Sep 2022.